Polycystic Ovary-Like Abnormalities (PCO-L) in Women with Functional Hypothalamic Amenorrhea
Overview
Affiliations
Context: In the general population, about 30% of asymptomatic women have polycystic ovary-like abnormalities (PCO-L), i.e. polycystic ovarian morphology (PCOM) at ultrasound and/or increased anti-Müllerian hormone (AMH) serum level. PCOM has also been reported in 30-50% of women with functional hypothalamic amenorrhea (FHA).
Objective: The aim of this study was to verify whether both PCOM and excessive AMH level indicate PCO-L in FHA and to elucidate its significance.
Design: We conducted a retrospective analysis using a database and comparison with a control population.
Setting: Subjects received ambulatory care in an academic hospital.
Patients: Fifty-eight patients with FHA were compared to 217 control women with nonendocrine infertility and body mass index of less than 25 kg/m(2).
Interventions: There were no interventions.
Main Outcome Measures: We measured serum testosterone, androstenedione, FSH, LH, AMH, and ovarian area values. The antral follicle count (AFC) was used as a binary variable (i.e. negative or positive) because of the evolution of its sensitivity over the time of this study. The ability of these variables (except AFC) to detect PCO-L in both populations was tested by cluster analysis.
Results: One cluster (cluster 2) suggesting PCO-L was detected in the control population (n = 52; 24%), whereas two such clusters were observed in the FHA population (n = 22 and n = 6; 38 and 10%; clusters 2 and 3, respectively). Cluster 2 in FHA had similar features of PCO-L as cluster 2 in controls, with higher prevalence of positive AFC (70%) and PCOM (70%), higher values of ovarian area and higher serum AMH (P < 0.0001 for all), and testosterone levels (P < 0.01) than in cluster 1. Cluster 3 in FHA was peculiar, with frankly elevated AMH levels. In the whole population (controls + FHA), PCO-L was significantly associated with lower FSH values (P < 0.0001).
Conclusion: PCO-L in FHA is a frequent and usually incidental finding of unclear significance, as in controls. The association of PCO-L with hypothalamic amenorrhea should not lead to a mistaken diagnosis of PCOS.
Ott J, Robin G, Hager M, Dewailly D Hum Reprod Update. 2024; 31(1):64-79.
PMID: 39378412 PMC: 11696701. DOI: 10.1093/humupd/dmae030.
The LH:FSH Ratio in Functional Hypothalamic Amenorrhea: An Observational Study.
Boegl M, Dewailly D, Marculescu R, Steininger J, Ott J, Hager M J Clin Med. 2024; 13(5).
PMID: 38592037 PMC: 10931730. DOI: 10.3390/jcm13051201.
Liu S, Zhou X, Jie H, Zheng Z, Cai B, Mai Q Int J Womens Health. 2024; 16:289-298.
PMID: 38415060 PMC: 10898478. DOI: 10.2147/IJWH.S445021.
Vanden Brink H, Burgert T, Barral R, Malik A, Gadiraju M, Lujan M J Pediatr Adolesc Gynecol. 2024; 37(3):315-322.
PMID: 38395192 PMC: 11195913. DOI: 10.1016/j.jpag.2024.02.004.
Prolactin levels in functional hypothalamic amenorrhea: a retrospective case-control study.
Selzer C, Ott J, Dewailly D, Marculescu R, Steininger J, Hager M Arch Gynecol Obstet. 2023; 309(2):651-658.
PMID: 37957366 PMC: 10808163. DOI: 10.1007/s00404-023-07277-1.